01890oam 2200481 450 991071654370332120210630085632.040-555(CKB)5470000002522719(OCoLC)1257552450(EXLCZ)99547000000252271920210625d2021 ua 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierImproving drug pricing transparency and lowering prices for American consumers hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Sixteenth Congress, first session, May 21, 2019Washington :U.S. Government Publishing Office,2021.1 online resource (vi, 187 pages) color illustrationsAccess ID (govinfo): CHRG-116hhrg40555."Serial no. 116-37."Includes bibliographical references.Improving drug pricing transparency and lowering prices for American consumers DrugsPricesUnited StatesPharmaceutical industryUnited StatesPrescription pricingUnited StatesPrescription pricingLaw and legislationUnited StatesInsurance premiumsLaw and legislationUnited StatesLegislative hearings.lcgftDrugsPricesPharmaceutical industryPrescription pricingPrescription pricingLaw and legislationInsurance premiumsLaw and legislationGPOGPOOCLCOGPOBOOK9910716543703321Improving drug pricing transparency and lowering prices for American consumers3440425UNINA